DAPA-CKD trial for Farxiga is stopped early in patients with chronic kidney disease due to overwhelming efficacy.- AstraZeneca
Related news and insights
Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug BAY 94 8862 (finerenone) versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint.
Bayer announced that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug BAY 94 8862 (finerenone) slowed the progression of chronic kidney disease (CKD) in patients with CKD and type 2 diabetes (T2D) compared to placebo. In the study, finerenone significantly reduced the risk of the composite primary endpoint of time to kidney failure